Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Inactivated types 1, 2, and 3 poliovirus, D antigens · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group A | EXPERIMENTAL | Will receive fractional doses of IPV Intradermally |
| Group B | ACTIVE_COMPARATOR | Will receive full doses of IPV Intramuscularly |
| Name | Type | Description |
|---|---|---|
| Inactivated types 1, 2, and 3 poliovirus, D antigens | BIOLOGICAL | 0.1 mL, intradermal |
Inclusion Criteria: * Aged 15 to 18 months on the day of inclusion * Informed consent form signed by the parent(s) or other legally acceptable representative * Subjects and parent/guardian able to attend all scheduled visits and comply with all trial procedures * Child having completed all visits o...
Inactivated types 1, 2, and 3 poliovirus, D antigens is used for poliomyelitis, commonly called polio. It is the antigen component of an inactivated polio vaccine designed to stimulate immune protection against all three poliovirus types. Sanofi is the developer of this vaccine asset.
Sanofi develops inactivated types 1, 2, and 3 poliovirus, D antigens. Sanofi trades under the ticker SNY. The asset is an inactivated polio vaccine antigen candidate studied for poliomyelitis prevention.
Inactivated types 1, 2, and 3 poliovirus, D antigens is in Phase 2 clinical development. It is investigational and has been studied in one completed Phase 2 trial. No active trials of this asset are currently listed.
Inactivated types 1, 2, and 3 poliovirus, D antigens was studied in trial NCT00885157, titled Immunogenicity and Safety of a Fractional Booster Dose of IPV Intradermally Versus Full Dose Intramuscularly. That Phase 2 trial was completed, enrolled 225 participants in the Philippines, and included healthy volunteers aged 15 months and older.
The Phase 2 trial NCT00885157 for inactivated types 1, 2, and 3 poliovirus, D antigens was an active-controlled study comparing a fractional intradermal booster dose of IPV with a full intramuscular dose. It enrolled 225 participants of all sexes in the Philippines and was completed.